Based on ideas of the founders, the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.
The approach defines a platform technology which is broadly applicable to a range of clinical indications with significant unmet medical need.
Allero’s proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with targeted delivery of specific antigens to the oral mucosa, an immune-priviliged target. The goal is to restore normal immune balance, avoiding global immune suppression, and treating the cause of the disease.
Tolerance Inducing Agent
Muco-adhesive Delivery Technology
Platfom that can be used for multiple allergy and auto-immune indications.
Enhances tolerance induction by stimulation of proper immune cells.
Optimal retention of therapeutics at common tolerance induction site: the oral mucosa.
Non-invasive and patient-friendly treatment.
Short-course treatment that reinstates tolerance with a long-lasting effect.
Safety key technology components validated in humans.